全文获取类型
收费全文 | 2546篇 |
免费 | 440篇 |
国内免费 | 172篇 |
出版年
2024年 | 14篇 |
2023年 | 52篇 |
2022年 | 85篇 |
2021年 | 123篇 |
2020年 | 122篇 |
2019年 | 134篇 |
2018年 | 112篇 |
2017年 | 94篇 |
2016年 | 92篇 |
2015年 | 127篇 |
2014年 | 202篇 |
2013年 | 184篇 |
2012年 | 161篇 |
2011年 | 202篇 |
2010年 | 118篇 |
2009年 | 97篇 |
2008年 | 135篇 |
2007年 | 129篇 |
2006年 | 112篇 |
2005年 | 93篇 |
2004年 | 86篇 |
2003年 | 83篇 |
2002年 | 61篇 |
2001年 | 43篇 |
2000年 | 42篇 |
1999年 | 33篇 |
1998年 | 44篇 |
1997年 | 56篇 |
1996年 | 24篇 |
1995年 | 33篇 |
1994年 | 47篇 |
1993年 | 25篇 |
1992年 | 31篇 |
1991年 | 37篇 |
1990年 | 22篇 |
1989年 | 31篇 |
1988年 | 13篇 |
1987年 | 10篇 |
1986年 | 13篇 |
1985年 | 10篇 |
1984年 | 7篇 |
1983年 | 6篇 |
1982年 | 7篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1976年 | 1篇 |
排序方式: 共有3158条查询结果,搜索用时 808 毫秒
991.
Hepatitis B is a vaccine preventable disease caused by the hepatitis B virus (HBV) that can induce potentially fatal liver damage. It has the second highest mortality rate of all vaccine preventable diseases in New Zealand. Vaccination against HBV was introduced in New Zealand in 1988, and the country is now categorised with overall low endemicity but with areas of both high and medium endemic levels. We present an SECIR compartmental mathematical model, with the population divided into age classes, for the transmission of HBV using local data on incidence of infection and vaccination coverage. We estimate the basic reproduction number, R0, to be 1.53, and show that the vaccination campaign has substantially reduced this below one. However, a large number of carriers remain in the population acting as a source of infection. 相似文献
992.
Yalamanchili N Syed R Chandra M Satti V Rao R Mohammed AH Nanne KM 《Indian journal of human genetics》2011,17(1):17-21
INTRODUCTION:
Designing a rapid, reliable and sensitive assay for detection of hepatitis B virus (HBV) variants by real-time PCR is challenging at best. A recent approach for quantifying the viral load using a sensitive fluorescent principle was brushed in this study.MATERIALS AND METHODS
: A total of 250 samples were collected from the outpatient unit, CLRD. Complete Human HBVDNA sequences (n = 944) were selected from the National Centre for Biotechnology Information (NCBI), primers and probes were designed and synthesized from the core, surface, and x region. Real-time based quantification was carried out using a standard kit and in-house generated standards and RT-PCR protocols.RESULTS AND DISCUSSION:
The standard calibration curve was generated by using serial dilution 102 to 108. The calibration curve was linear in a range from 102 to 108 copies/ml, with an R2 value of 0.999. Reproducibility as measured by dual testing of triplicates of serum samples was acceptable, with coefficients of variation at 6.5%, 7.5%, and 10.5%. Our results showed that amplification performance was good in the case of the x-region-based design (98%). Out of 100 negative samples screened by enzyme linked immunosorbent assay and the standard RT-PCR kit, one sample was detected as positive with the in-house developed RT-PCR assay, the positivity of the sample was confirmed by sequencing the amplified product, NCBI accession . EU684022CONCLUSION:
This assay is reproducible showing limited inter- and intra-assay variability. We demonstrate that the results of our assay correlated well with the standard kit for the HBV viral load monitor. 相似文献993.
为研制新型有效的HBV治疗性疫苗,构建了含PreS1与S融合基因的HBV DNA疫苗,即pVRC-HBSS1 (PreS1 21–47 aa融合在S抗原1–223的羧基端),并制备了CHO表达相同结构的蛋白颗粒亚单位疫苗HBSS1。在Balb/C小鼠中采用不同的DNA免疫方式 (即肌肉注射、皮内注射加电转) 初免3次,蛋白颗粒亚单位疫苗 (不同佐剂) 肌肉注射加强免疫1次,然后我们分析比较了各组疫苗所引起的免疫应答特点。抗体检测结果表明:皮内注射结合电转初免组产生的PreS1与 S特异性抗体水平皆高于肌肉直接注射组。进一步还发现DNA疫苗与蛋白颗粒亚单位疫苗两种疫苗联合应用后S抗原特异的细胞免疫应答 (IFN-γ ELISpot分析) 明显高于DNA疫苗或蛋白颗粒亚单位单独应用,其中皮内注射+电转结合蛋白颗粒亚单位疫苗联合免疫组可产生最强的细胞免疫应答。这些研究为新型HBV 治疗性疫苗的优化设计与合理应用提供了依据。 相似文献
994.
Inhibition of Hepatitis B virus cccDNA replication by siRNA 总被引:6,自引:0,他引:6
995.
Katavetin P Inagi R Miyata T Shao J Sassa R Adler S Eto N Kato H Fujita T Nangaku M 《Biochemical and biophysical research communications》2007,359(4):928-934
Recent studies have established that erythropoietin (EPO) is a pleiotropic cytokine. In this study we investigated whether pleiotropic effects of EPO may involve regulation of heme oxygenase (HO)-1, an anti-oxidative stress protein. A stimulatory effect of EPO on HO-1 expression was demonstrated in cultured renal endothelial cells, in which EPO decreased intracellular oxidative stress and provided cytoprotection against H(2)O(2). These beneficial effects were partially reversed by a HO-1 inhibitor. We then evaluated whether EPO induces HO-1 and ameliorates renal injury in vivo. Administration of EPO to Dahl salt-sensitive (DS) rats with low salt diet, a model of chronic tubulointerstitial injury, reduced proteinuria, and renal injury including peritubular capillaries rarefaction as compared to vehicle-treated DS rats. This renoprotection was associated with up-regulation of HO-1 in the kidney. In conclusion, EPO-induced HO-1 expression is likely to provide cytoprotection against oxidative stress. 相似文献
996.
Evidence for cellular uptake of recombinant hepatitis C virus non-enveloped capsid-like particles 总被引:1,自引:0,他引:1
Tsitoura P Georgopoulou U Pêtres S Varaklioti A Karafoulidou A Vagena D Politis C Mavromara P 《FEBS letters》2007,581(21):4049-4057
Although the hepatitis C virus (HCV) is an enveloped virus, naked nucleocapsids have been reported in the serum of infected patients, and most recently novel HCV subgenomes with deletions of the envelope proteins have been identified. However the significance of these findings remains unclear. In this study, we used the baculovirus expression system to generate recombinant HCV capsid-like particles, and investigated their possible interactions with cells. We show that expression of HCV core in insect cells can sufficiently direct the formation of capsid-like particles in the absence of the HCV envelope glycoproteins and of the 5' untranslated region. By confocal microscopy analysis, we provide evidence that the naked capsid-like particles could be uptaken by human hepatoma cells. Moreover, our findings suggest that they have the potential to produce cell-signaling effects. 相似文献
997.
998.
Shara M Kincaid AE Limpach AL Sandstrom R Barrett L Norton N Bramble JD Yasmin T Tran J Chatterjee A Bagchi M Bagchi D 《Journal of inorganic biochemistry》2007,101(7):1059-1069
Chromium (III) is an essential micronutrient required for normal protein, fat and carbohydrate metabolism, as well as helps insulin metabolize fat, turn protein into muscle and convert sugar into energy. A broad spectrum of research investigations including in vitro, in vivo and clinical studies demonstrated the beneficial effects of novel oxygen- coordinated niacin-bound chromium (III) complex (NBC) in promoting glucose-insulin sensitivity, lipid profile, cardioprotective ability and lean body mass. This study examined the long-term safety of NBC by orally administering either 0 or 25 ppm or the human equivalency dose of 1000 microg elemental chromium (III) as NBC per day for 52 consecutive weeks to male and female Sprague-Dawley rats. Animals of each group and each gender were sacrificed on 26, 39, or 52 weeks of treatment. Body weight, physical and ocular health, feed and water intake, selected organ weights as such and as a percentage of liver and brain weight, hepatic lipid peroxidation and DNA fragmentation, hematology and clinical chemistry, and histopathological evaluations were conducted. At 26, 39, or 52 weeks of treatment, body weight gain was significantly reduced by 7.7%, 8.1% and 14.9% in male rats, and 5.5%, 11.4% and 9.6% in female rats, respectively, in the NBC treatment groups. No significant changes were observed in hepatic lipid peroxidation and DNA fragmentation, hematology and clinical chemistry, and histopathological evaluation between control and NBC groups at these time points. These findings, thus far, are in agreement with the subchronic studies in terms of the safety of NBC. 相似文献
999.
Mansour A Chang VT Srinivas S Harrison J Raveche E 《Cancer immunology, immunotherapy : CII》2007,56(4):501-514
The role of ZAP-70 expression on the ex vivo response of blood cells from CLL and PLL patients to a combination of fludarabine,
a purine analog, and genistein, a tyrosine kinase inhibitor was studied. Patient cells were studied for the expression of
ZAP-70 mRNA and its relation to the induction of apoptosis in response to treatment with genistein 15–60 μM and/or fludarabine
3 μM. The combination of genistein and fludarabine resulted in a significantly increased induction of apoptosis relative to
the fludarabine alone. The ex vivo patient cells with a high ZAP-70 expression underwent more apoptosis in response to genistein
than did patient cells with a low ZAP-70 mRNA expression. In contrast, basal IL-10 mRNA expression correlated negatively with
apoptosis induction in response to genistein (P < 0.01). These studies suggest that, in malignant B cells that express elevated levels of the ZAP-70 signaling molecule,
genistein may inhibit the ZAP-70 tyrosine kinase activity, resulting in cell death. The ZAP-70 may serve as a target for therapy.
In addition, these studies suggest that the IL-10 expression by malignant B cells may not only suppress anti-tumor T cell
responses in vivo, but also promote the survival of malignant B cells despite treatment with chemotherapeutic agents. 相似文献
1000.
Chen J Schmitt A Chen B Rojewski M Ringhoffer M von Harsdorf S Greiner J Guillaume P Döhner H Bunjes D Schmitt M 《Cancer immunology, immunotherapy : CII》2007,56(6):849-861
The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate is highly effective in the front-line treatment of chronic myeloid
leukemia (CML) and is increasingly used in patients with residual disease or relapse after allogeneic stem cell transplantation
(allo-SCT). Since an impairment of anti-viral CD8+ T-lymphocyte function by imatinib has been described, we question whether
imatinib also affects specific anti-leukemic CD8+ T lymphocytes generated from the peripheral blood of healthy donors, and
of CML patients after allo-SCT. Here, we assessed CD8+ T-cell expansion and function from healthy donors and patients with
CML. The release of IFN-γ and granzyme B by CD8+ T-lymphocytes specific for R3, a recently described T-cell epitope peptide
derived from a leukemia-associated antigen designated RHAMM/CD168 (receptor for hyaluronic acid mediated motility), was inhibited
by imatinib in a dose-dependent fashion (range: 1–25 μM). These T cells were able to lyse cognate peptide labeled T2 cells
and CD34+ CML progenitor cells. This lysis was inhibited by imatinib. The inhibitory effect was not associated with an increased
rate of apoptosis of T cells and reversible after removal of imatinib. In the light of these findings, clinical administration
of imatinib might result in the reduction of efficacy of the graft-versus-leukemia effect or other T-cell-based immunotherapies. 相似文献